Serum Selenium Levels in Patients with Graves Disease: Associations with Clinical Activity and Severity in a Retrospective Case-control Study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To compare serum selenium levels in Graves patients and non-Graves control participants and to evaluate associationsbetween serum selenium levels and clinical features of Graves orbitopathy (GO). Methods: We conducted a single-center, retrospective case-control study among 33 patients with Graves disease withoutGO (GD), 31 patients with diagnosed GO, and 27 unaffected healthy participants enrolled between 2013 and 2020 at SeveranceHospital. We compared serum selenium concentrations between the GD, GO, and healthy control groups, and analyzedassociations between serum selenium and GO patients’ clinical activity scores, severity (assessed through modified NOSPECSscores), and other clinical features using multivariate linear regression analysis. Results: Mean serum selenium levels were 109.30 ± 16.39, 111.39 ± 14.04, and 126.09 ± 21.09 ng/mL in GO patients, GDpatients, and healthy control participants, respectively. Mean serum selenium levels in Graves patients with and without orbitopathywere significantly lower than those in the healthy control group (p < 0.05), and mean selenium levels were slightlylower in GO than those in GD patients (p = 0.594). Serum selenium levels were significantly lower in GO patients with eyelidretraction than in patients without retraction (p = 0.038). However, serum selenium levels were not associated with clinicalactivity scores and modified NOSPECS scores (p = 0.241 and 0.801, respectively). Conclusions: Serum selenium levels were significantly lower in Graves patients with or without GO, compared to non-Gravescontrol participants. Selenium levels were not associated with clinical activity scores or NOSPECS scores, though we observedan association with eyelid retraction.
Abstract
Purpose: To compare serum selenium levels in Graves patients and non-Graves control participants and to evaluate associationsbetween serum selenium levels and clinical features of Graves orbitopathy (GO). Methods: We conducted a single-center, retrospective case-control study among 33 patients with Graves disease withoutGO (GD), 31 patients with diagnosed GO, and 27 unaffected healthy participants enrolled between 2013 and 2020 at SeveranceHospital. We compared serum selenium concentrations between the GD, GO, and healthy control groups, and analyzedassociations between serum selenium and GO patients’ clinical activity scores, severity (assessed through modified NOSPECSscores), and other clinical features using multivariate linear regression analysis. Results: Mean serum selenium levels were 109.30 ± 16.39, 111.39 ± 14.04, and 126.09 ± 21.09 ng/mL in GO patients, GDpatients, and healthy control participants, respectively. Mean serum selenium levels in Graves patients with and without orbitopathywere significantly lower than those in the healthy control group (p < 0.05), and mean selenium levels were slightlylower in GO than those in GD patients (p = 0.594). Serum selenium levels were significantly lower in GO patients with eyelidretraction than in patients without retraction (p = 0.038). However, serum selenium levels were not associated with clinicalactivity scores and modified NOSPECS scores (p = 0.241 and 0.801, respectively). Conclusions: Serum selenium levels were significantly lower in Graves patients with or without GO, compared to non-Gravescontrol participants. Selenium levels were not associated with clinical activity scores or NOSPECS scores, though we observedan association with eyelid retraction.
참고문헌 (35)
- Hiromatsu Y, "Graves’ ophthalmopathy : epidemiology and natural history", Intern Med, 53, pp.353~360 (2014)
- Wu Q, "Low population selenium status is associated with increased prevalence of thyroid disease", J Clin Endocrinol Metab, 100, pp.4037~4047 (2015)
- Rayman MP, "Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease", Proc Nutr Soc, 78, pp.34~44 (2019)
- Wichman J, "Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis : a systematic review and meta-analysis", Thyroid, 26, pp.1681~1692 (2016)
- Marcocci C, "Selenium and the course of mild Graves’ orbitopathy", N Engl J Med, 364, pp.1920~1931 (2011)
- Bartalena L, "The 2016 European Thyroid Association", European Group on Graves’Orbitopathy Guidelines for the management of Graves’ orbitopathy, 2016, pp.5, 9~26
- Johnson CC, "Symposium on ‘Geographical and geological influences on nutrition’ : factors controlling the distribution of selenium in the environment and their impact on health and nutrition", Proc Nutr Soc, 69, pp.119~132 (2010)
- Stoffaneller R, "A review of dietary selenium intake and selenium status in Europe and the Middle East", Nutrients, 7, pp.1494~1537 (2015)
- Ross DS, "2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis", Thyroid, 26, pp.1343~1421 (2016)
- Kim YJ, "Serum selenium level in healthy Koreans", Biol Trace Elem Res, 131, pp.103~109 (2009)
- Kim IW, "Serum selenium levels in Korean hepatoma patients", Biol Trace Elem Res, 148, pp.25~31 (2012)
- Mourits MP, "Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy", Clin Endocrinol(Oxf), 47, pp.9~14 (1997)
- Eckstein AK, "Thyrotropin receptor autoantibodies are independent risk factors for Graves’ophthalmopathy and help to predict severity and outcome of the disease", J Clin Endocrinol Metab, 91, pp.3464~3470 (2006)
- Sohn OS, "Excretion and tissue distribution of selenium following treatment of male F344rats with benzylselenocyanate or sodium selenite", Drug Metab Dispos, 19, pp.865~870 (1991)
- Negro R, "A 2018 European Thyroid Association Survey on the use of selenium supplementation in Graves’ hyperthyroidism and Graves’ orbitopathy", Eur Thyroid J, 8, pp.7~15 (2019)
- Khong JJ, "Serum selenium status in Graves’ disease with and without orbitopathy:a case-control study", Clin Endocrinol (Oxf ), 80, pp.905~910 (2014)
- Dehina N, "Lack of association between selenium status and disease severity and activity in patients with Graves’ ophthalmopathy", Eur Thyroid J, 5, pp.57~64 (2016)
- Winther KH, "Selenium in thyroid disorders : essential knowledge for clinicians", Nat Rev Endocrinol, 16, pp.165~176 (2020)
- Tinggi U, "Selenium : its role as antioxidant in human health", Environ Health Prev Med, 13, pp.102~108 (2008)
- Lanzolla G, "Oxidative stress in graves disease and graves orbitopathy", Eur Thyroid J, 9(Suppl 1), pp.40~50 (2020)
- Bartalena L, "Oxidative stress and Graves’ ophthalmopathy : in vitro studies and therapeutic implications", Biofactors, 19, pp.155~163 (2003)
- Ventura M, "Selenium and thyroid disease : from pathophysiology to treatment", Int J Endocrinol, 2017, pp.1297658~ (2017)
- Lee YH, "Serum selenium levels in patients with respiratory diseases : a prospective observational study", J Thorac Dis, 8, pp.2068~2078 (2016)
- Rua RM, "Serum selenium levels and oxidative balance as differential markers in hepatic damage caused by alcohol", Life Sci, 94, pp.158~163 (2014)
- Ravn-Haren G, "A short-term intervention trial with selenate, selenium-enriched yeast and selenium-enriched milk: effects on oxidative defence regulation", Br J Nutr, 99, pp.883~892 (2008)
- Alfthan G, "Selenium supplementation of children in a selenium-deficient area in China : blood selenium levels and glutathione peroxidase activities", Biol Trace Elem Res, 73, pp.113~125 (2000)
- Thomson CD, "Long-term supplementation with selenate and selenomethionine:selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New Zealand women", Br J Nutr, 69, pp.577~588 (1993)
- Combs GF Jr, "Selenium in global food systems", Br J Nutr, 85, pp.517~547 (2001)
- Stranges S, "Effects of longterm selenium supplementation on the incidence of type 2diabetes : a randomized trial", Ann Intern Med, 147, pp.217~223 (2007)
- Esperidiao-Antonio V, "The human superior tarsal muscle(Müller’s muscle) : a morphological classification with surgical correlations", Anat Sci Int, 85, pp.1~7 (2010)
- Bahn RS, "Graves’ ophthalmopathy", N Engl J Med, 362, pp.726~738 (2010)
- Feldon SE, "Graves’ ophthalmopathy: V. Aetiology of upper eyelid retraction in Graves’ ophthalmopathy", Br J Ophthalmol, 74, pp.484~485 (1990)
- Smith TJ, "Pharmacotherapy: does selenium supplementation improve Graves ophthalmopathy?", Nat Rev Endocrinol, 7, pp.505~506 (2011)
- Campese VM, "Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity", Am J Physiol Heart Circ Physiol, 287, pp.H695~703 (2004)
- Ye S, "Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension", Hypertension, 48, pp.309~315 (2006)